An Open Label Pharmacokinetic Study Of Gabapentin In Japanese Subjects With Renal Impairment Including Hemodialysis
Overview
To confirm the pharmacokinetics following administration of gabapentin to Japanese subjects with renal impairment, compare the results to Western study results and confirm the adaptive possibility of dose adjustment in US package insert to Japanese.
Study Type
- Study Type: Interventional
- Study Design
- Allocation: N/A
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
- Study Primary Completion Date: December 2007
Detailed Description
The study was terminated on September 30, 2008 at the current study site due to reported adverse events in the study subjects (n=8). While the adverse events reported were generally consistent with the known profile of gabapentin, it was decided that the study should continue at a different study site. The pharmacokinetics of gabapentin in the subjects with renal impairment will be evaluated in a separate study with a different study number at a different site. The study will be entitled: "The Pharmacokinetic Study of Gabapentin in Japanese Epileptic Subjects with Renal Impairment".
Interventions
- Drug: Gabapentin
- CLcr:14-5 mL/min
- Drug: Gabapentin
- CLcr: 29-15 mL/min
- Drug: Gabapentin
- Hemodialysis
- Drug: Gabapentin
- CLcr: 29-30 mL/min
Arms, Groups and Cohorts
- Experimental: 1
- Experimental: 2
- Experimental: 3
- Experimental: 4
Clinical Trial Outcome Measures
Primary Measures
- Pharmacokinetics
- Time Frame: dec 2008
Secondary Measures
- There were no secondary outcomes measures for this study
- Time Frame: dec 2008
Participating in This Clinical Trial
Inclusion Criteria
- The subjects whose creatinine clearance is 5-59 mL/min, or hemodialysis patients. – The hemodialysis patients who enter this study is required hemodialysis for at least six weeks (the frequency is three times per week) Exclusion Criteria:
- Renal allograft recipients
Gender Eligibility: All
Minimum Age: 20 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: Accepts Healthy Volunteers
Investigator Details
- Lead Sponsor
- Pfizer’s Upjohn has merged with Mylan to form Viatris Inc.
- Provider of Information About this Clinical Study
- Sponsor
- Overall Official(s)
- Pfizer CT.gov Call Center, Study Director, Pfizer
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.